Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma

Abstract

an approximate half-life of 24 to 48 hours, there may have been residual sorafenib present during radiation treatment and thus normal tissue was still radiosensitized via sorafenib. This report describes a patient receiving sorafenib that developed a lumbar metastasis that required irradiation. She died of complications in the bowel-the area directly targeted by irradiation. In conclusion, this case provides evidence for potential oversensitization of normal tissue by sorafenib. Further studies combining antiangiogenic therapy with radiotherapy are warranted in order to further determine the efficacy and toxicity of combination therapy of sorafenib with radiation.

The Tumor Lysis Syndrome

“…1-4 Although it develops most often in patients with non-Hodgkin’s lymphoma or acute leukemia, its frequency is increasing among patients who have tumors that used to be only rarely associated with this complication. 5-8 The tumor lysis syndrome occurs when tumor cells release their contents into the bloodstream, either spontaneously or in response to therapy, leading to the characteristic findings of hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. 1-3 These electrolyte and metabolic disturbances can progress to clinical toxic effects, including renal insufficiency, cardiac arrhythmias, seizures, and death due to multiorgan failure.…”

Tumor Lysis Syndrome in a Patient with Metastatic Colon Cancer after Treatment with 5-Fluorouracil/Leucovorin and Oxaliplatin: Case Report and Literature Review

“…The first such patient, who had a widespread adenocarcinoma of gastrointestinal origin with renal failure, was reported in 1977 [4], and an additional 74 patients with solid tumors who developed TLS were reported between 1977 and 2011. These solid tumors included breast cancer, small cell lung cancer, germ cell tumor, melanoma, Merkel cell carcinoma, head and neck cancer, non-small cell lung cancer, ovarian cancer, vulva cancer, prostate cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, sarcoma, neuroblastoma, medulloblastoma, hepatoblastoma, gestational trophoblastic neoplasia, renal cell carcinoma, transitional cell carcinoma, and thymoma [1,5,6,7,8,9,10,11,12,13]. …”

A case of cetuximab-related tumour lysis syndrome in metastatic rectal carcinoma

“…Though he had the background history of primary hypertension for about 10 years, it was well controlled; he was normotensive even during his inpatient stay when he was resuscitated with intravenous fluids. To the best of our knowledge, there is only one other case report of tumour lysis syndrome with cetuximab use [6]. These collected case reports highlight that TLS can also develop in ‘low risk’ category tumours, and the clinicians should be vigilant in identifying at-risk patients.…”

“…Here, we report a case of tumour lysis syndrome induced by cetuximab. To our knowledge, there is only one other case report of tumour lysis syndrome with cetuximab use [6]. …”